European Medicine Supply at Risk as Directive on Wastewater Treatment Faces Scrutiny
Prague, February 24, 2026 – A critical debate is unfolding over the potential impact of a new European Union directive on the availability of essential medicines. Zentiva, a leading European manufacturer of affordable, high-quality pharmaceuticals, is urgently calling for a pause in the implementation of the EU’s revised rules on urban wastewater treatment, arguing that the current framework poses a significant threat to the security of medicine supply across the continent. The dispute centers on the financial burden the directive places on pharmaceutical companies, requiring them to contribute substantially to the costs of advanced wastewater treatment – a cost Zentiva argues is unsustainable for producers of generic and off-patent medications.
The core of the issue lies in the EU’s directive on the treatment of urban wastewater, which aims to improve water quality by requiring more advanced treatment processes. These processes, particularly the fourth stage of treatment, are designed to remove emerging pollutants, including pharmaceutical residues. However, the directive mandates that the pharmaceutical and cosmetic industries cover at least 80% of the costs associated with this fourth stage, a provision that Zentiva and other generic drug manufacturers contend is economically unviable. Generic medications, by their nature, operate on very thin profit margins, often priced at just a few cents per dose due to regulatory controls and competitive pressures.
Zentiva’s concerns aren’t falling on deaf ears. Sixteen EU member states initially raised major concerns about the directive’s potential consequences, prompting Zentiva to launch a legal challenge in 2025 seeking its annulment. While the European Court of Justice recently ruled that Zentiva lacked the standing to directly challenge the directive – finding that the company and similar manufacturers weren’t individually affected enough to pursue legal action – the court did not rule on the substance of the directive itself. This means the fundamental questions surrounding its feasibility, proportionality, and potential impact on medicine supply remain unanswered. The ruling, according to Zentiva, underscores the demand for political intervention to address the looming crisis.
Legal Setback, But Fight Continues
The European Court of Justice’s decision, while a setback for Zentiva’s legal strategy, doesn’t resolve the underlying issues. As Steffen Saltofte, CEO of Zentiva and President of Medicines for Europe, explained, the directive is based on scientific assessments that have been repeatedly refuted. “The directive was approved and is already being implemented,” Saltofte stated. “It relies on an assessment that has been scientifically refuted repeatedly, yet it obliges the pharmaceutical and cosmetic industries to cover at least 80% of the costs of wastewater treatment during the fourth treatment phase. We knew from the outset that this was not possible for the off-patent medicine industry. Our prices are mostly regulated and the price of a daily dose of a non-patented medicine is in the order of a euro cent. We simply cannot absorb these costs.”
The potential consequences of implementing the directive without modification are significant. Zentiva warns that the increased financial burden could render the production of many essential medicines economically unviable, leading to shortages and reduced access to affordable treatments for patients across the EU. The generic drug industry plays a crucial role in healthcare systems throughout Europe, accounting for approximately 70% of all dispensed medicines and 9 out of 10 essential medications, according to Zentiva. A disruption to this sector could have far-reaching implications for public health.
The situation is further complicated by the fact that the directive is already being implemented at the national level in various EU member states. This makes a coordinated response and potential revisions all the more urgent. Zentiva is actively advocating for a pause in implementation to allow for a comprehensive dialogue involving EU institutions, member states, water sector operators, patient organizations, healthcare systems, and the pharmaceutical industry.
The Extended Producer Responsibility (EPR) Model Under Fire
At the heart of the controversy is the Extended Producer Responsibility (EPR) model embedded within the directive. This principle holds producers responsible for the end-of-life management of their products, in this case, the pharmaceutical residues found in wastewater. While EPR is a common approach in environmental policy, Zentiva argues that its application to the pharmaceutical industry is disproportionate and impractical. The company contends that the cost allocation is not feasible, proportionate, or safe for ensuring the continued supply of medicines.
The financial implications are substantial. The directive effectively shifts a significant portion of the cost of upgrading wastewater treatment infrastructure onto pharmaceutical companies, costs that were previously borne by municipalities and taxpayers. This shift, Zentiva argues, fails to recognize the unique economic realities of the generic drug market, where razor-thin margins are the norm.
The debate also raises broader questions about the balance between environmental protection and access to essential medicines. While improving water quality is a laudable goal, Zentiva argues that it should not come at the expense of patient health and affordability. The company emphasizes the need for a solution that protects both the environment and the availability of vital medications.
Calls for Dialogue and Revised Assessment
Zentiva is urging for several key actions to address the crisis. These include a pause in the current implementation of the directive to facilitate an inclusive dialogue, the commissioning of new independent studies based on robust scientific data, proportionality, and the real economics of healthcare to assess the impact on medicine availability, accessibility, and affordability, and a relaunch of the directive in a viable form that ensures clean water without compromising access to essential medicines.
Saltofte emphasized the need for a collaborative approach, stating, “As CEO of a European company and President of Medicines for Europe, representing the off-patent medicine industry, I will not stand idly by in this situation. We will continue to insist on a solution to be developed together, not in isolation, and not without the industry. This issue requires all stakeholders to be brought to the same table to suspend the implementation of the directive, revise it at the EU level, and relaunch it in a viable manner across Europe, ensuring clean water without compromising the availability, accessibility, and affordability of healthcare for the people who depend on these medicines in Europe every day.”
What Happens Next?
The directive is currently being transposed into national legislation across the 27 EU member states. This ongoing implementation underscores the urgency of the situation and the need for swift political action. Zentiva’s call for a pause and a comprehensive review is gaining traction, but the outcome remains uncertain. The European Commission, responsible for proposing and overseeing EU legislation, will be under increasing pressure to address the concerns raised by Zentiva and other stakeholders.
The potential for medicine shortages is a real and pressing concern. If the directive is implemented in its current form, it could lead to widespread disruptions in the supply of essential medications, impacting patients across Europe. The situation highlights the complex interplay between environmental policy, public health, and the pharmaceutical industry. Finding a sustainable solution will require a collaborative effort and a willingness to compromise.
Zentiva’s position is supported by Medicines for Europe, the trade association representing the generic, biosimilar and off-patent medicine industries in Europe. Medicines for Europe advocates for policies that promote access to affordable medicines and ensure the sustainability of the generic industry.
Key Takeaways:
- The EU’s new wastewater treatment directive could significantly increase costs for generic drug manufacturers.
- Zentiva is warning of potential medicine shortages if the directive is implemented in its current form.
- The company is calling for a pause in implementation and a comprehensive review of the directive’s impact.
- The debate highlights the tension between environmental protection and access to affordable healthcare.
The coming months will be critical in determining the future of medicine supply in Europe. The European Commission is expected to respond to the concerns raised by Zentiva and other stakeholders in the near future. Further updates will be provided as the situation develops. Share your thoughts on this important issue in the comments below.